“There are two realities in drug discovery,”
says Don Frail, chief scientific officer of Pfizer’s Indications Discovery Unit.
“The majority of candidates tested in development do not give the desired result, yet those drugs that do succeed typically have multiple uses.”
Pfizer, Washington University $ 22.5 M collaboration – May 2010.
(Pfizer Press Release – 5/17/2010)